Sativa Wellness hails publication of research paper on effects of cannabinoids on lung inflammation

Sativa Wellness Group Inc (LON:SWEL) said following its collaboration with King’s College London, a research paper has been published which includes the results of an investigation on the potential therapeutic use of cannabinoids for the treatment of respiratory diseases. The company said the primary purpose of the study was to investigate the anti-inflammatory effects of two of the non-psychotropic cannabinoids, cannabidiol (CBD) and cannabigerol (CBG) alone and in combination, in a model of pulmonary inflammation. READ: Sativa Wellness says trading goes strongly after first-quarter revenues, profits soar Sativa added that the results of the work suggest that CBD and CBG in combination have “significant anti-inflammatory activity” in the lung and that the work undertaken builds on previous research that suggests cannabinoids are promising potential treatments for inflammatory diseases. The company also said that another part of the research has identified that the formulation for administering cannabinoids is critically important to obtain efficacy and “highlights the importance of choosing an appropriate formulation to obtain optimal benefit from administering cannabinoids”. "We have actively supported research now for over 2 years to identify the therapeutic benefits cannabinoids can have on medical conditions. Research is something we as a company believe is essential to inform the public and we are delighted to have seen such positive results identified. Sativa Group will continue to invest in scientific research to ensure that the cannabinoid products it develops under 'Goodbody Botanicals' and 'Goodbody Store', deliver the appropriate benefits", Sativa’s executive chairman Geremy Thomas said in a statement.